A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed, Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Principal Investigator
Floor Backes, MD
Status
Closed to Accrual & Treatment
Date Opened To Accrual
February 07 2020
Date Closed to Accrual
August 29 2022
Disease Site
Gynecologic [GY]
Uterine Corpus
Phase
III
Developmental Therapeutics
No
Primary Objective
To compare the 3-year recurrence-free survival of women with high intermediate risk (HIR) Stage I/II mismatch repair deficient (dMMR) endometrioid endometrial cancer treated with radiation and MK-3475 (pembrolizumab) versus radiation alone.
Patient Population
Women with Stage I or II endometrioid endometrial cancer with documented MMR deficiency.
Target Accrual
168
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.